About

Caldrin is an independent resource on the emerging evidence, limitations, and safety considerations surrounding ibogaine and anxiety. It emphasizes that ibogaine remains investigational and high risk.

We provide clear, evidence-first context about treatments and research so readers can weigh potential benefits and harms. Our content is written for patients, families, and professionals seeking cautious, understandable information.

For program descriptions and clinical services, please consult licensed providers listed externally; Caldrin does not provide treatment.

Close-up photographic detail related to clinical discussion of ibogaine and anxiety, calm editorial crop

Our editorial approach

How we select and vet information

Caldrin curates and summarizes primary literature, trial registries, and official guidance to produce plain-language syntheses. We prioritize peer-reviewed studies, clinical trial registries, and established regulatory or academic sources when assessing claims about investigational treatments.

When we reference clinical activity or programs, we provide context rather than endorsement; for example, readers seeking operational details for treatment providers may consult external directories such as ibogaine treatment center listings, but Caldrin itself is not a clinic (regional treatment listings and directories).

To support methodological transparency, we link to authoritative policy or evidence-synthesis resources when making procedural or safety claims. For example, general principles of clinical research governance and trial registration are informed by standards at ClinicalTrials.gov and the World Health Organization's registry guidance (ClinicalTrials.gov) and global registry practices summarized by the WHO (WHO clinical trial registry guidance).

What we cover

Caldrin focuses on high-level, evidence-focused material: summaries of clinical studies, methodological caveats, safety and screening considerations, trial design issues, and how evidence should inform patient decisions. We mention the site's topic—Ibogaine Treatment For Anxiety—only to clarify scope; the About page concentrates on how we operate as a resource.

Organization of content

Content is organized into thematic sections: overview synopses, clinical evidence, safety and screening guidance, and research pathways. Each section links back to topical pages — for example, our services overview explains the types of information we publish and links to operational descriptions on our Services page where appropriate.

Editorial principles

Guiding values that shape every summary we publish

Independence — We publish without financial ties to treatment providers.
Evidence before hype — Claims are grounded in peer-reviewed literature or trial registrations.
Clear risk communication — We emphasize uncertainty, adverse outcomes, and contraindications.
Plain language — Technical material is translated into clear summaries for non‑specialists.
Scientific humility — We avoid definitive claims when evidence is limited.

Independent by design

Caldrin is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its content is not medical or legal advice. We recommend readers consult licensed clinicians and official registries for clinical decisions; for example, trial listings and regulatory notices are available on sites such as Wikipedia's clinical trial overview and government registries like ClinicalTrials.gov.

If you arrived here from an external directory and are looking for clinical services, verify provider credentials through official channels; Caldrin does not endorse or contract with treatment providers.

Return to our main summaries any time via the site's front page where topical syntheses and the latest updates are published (see the site's introduction at Caldrin's main pages).